In addition, long-term administration of Shuganjieyu capsule can downregulate the activities of CYP1A2 and CYP2C19 enzymes in CUMS depression model rats by inhibiting the expression of CYP1A2 and CYP2C19 proteins and CYP1A2 mRNA, indicating that the metabolism of Shuganjieyu capsule in the liver is mainly through two CYP450 enzyme subtypes of CYP1A2 and CYP2C19, and may affect the bioavailability of drugs metabolized by CYP1A2 and CYP2C19 enzymes. The gene discussed is CYP1A2; the disease is depressive disorder.